| Document |
Document Title |
|
WO/2023/128906A1 |
The present invention relates to pharmaceutical composition comprising propiverine or a pharmaceutically acceptable salt thereof is in the sustained release coated with enteric coating layer comprising pH modifying agent to reduce drug r...
|
|
WO/2023/127883A1 |
The present invention provides a compound indicated by general formula (1) and having mPGES-1 inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, R1 and R2 each independently indicate hy...
|
|
WO/2023/122656A1 |
The present disclosure provides methods of treating a subject having a kidney disease or at risk of developing a kidney disease by administering an Angiopoietin Like 3 (ANGPTL3) inhibitor, and methods of identifying subjects having an in...
|
|
WO/2023/118092A1 |
The present invention relates to substituted pyrazolo[l,5-a]pyridine-[3,2-e]pyrimidines compounds of formula (I) wherein X, R1, and R2 are as defined in the claims, methods of preparing said compounds, pharmaceutical compositions and com...
|
|
WO/2023/117659A1 |
The present disclosure generally relates to methods and compositions comprising urolithin that treat or prevent a disease or condition associated with muscle decline and/or a kidney dysfunction. Moreover, methods and compositions compris...
|
|
WO/2023/122433A1 |
The present disclosure relates to gene editing systems and/or compositions comprising RNA guides targeting HAO1 and RNA guides targeting LDHA. Also provide herein are methods of using the gene editing system for introducing edits to the ...
|
|
WO/2023/118968A2 |
Disclosed herein are methods of detecting xanthine oxidase expression in polycystic kidney disease, or methods of delaying the onset or treating polycystic kidney disease, or both. The inventors have made the remarkable discovery that ab...
|
|
WO/2023/117189A1 |
The invention relates to a composition for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory tract infection, a bacterial soft tissue infection and a bacterial bo...
|
|
WO/2023/111861A1 |
Disclosed herein are methods of treating or preventing prostate cancer in a subject, the methods comprising administering to the subject a treatment regimen comprising two or more vaccines comprising a great ape adenovirus serotype 20 (G...
|
|
WO/2023/114170A1 |
The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I) and pharmaceutically acceptable salts thereof, wherein Cy, R1and R2 are as defined herein. The in...
|
|
WO/2023/113355A1 |
The present invention relates to a pharmaceutical composition including a Platycarya strobilacea extract as an active ingredient for prevention or treatment of vascular calcification. Being free of cytotoxicity and having an inhibitory e...
|
|
WO/2023/111196A1 |
Antagonists of interleukin 11 (IL-11)-mediated signalling are disclosed. Also disclosed are pharmaceutical compositions, antibodies, antigen binding fragments, antisense oligonucleotides, siRNA molecules, pharmaceutical combinations, and...
|
|
WO/2023/113023A1 |
The present invention provides: a compound that has an inhibitory action against hematopoietic prostaglandin D synthase (H-PGDS), and thus is useful for the prevention and treatment of diseases in which the enzyme is involved; and a phar...
|
|
WO/2023/109826A1 |
The present application relates to a use of silver carbonate in preparation of a medicament. The medicament is used for treating and/or relieving diseases or conditions related to electrolyte imbalance in a subject. The diseases or condi...
|
|
WO/2023/113706A1 |
The present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof with at least two hydrogel forming agents and a binder to obtain improved release profile in three diffe...
|
|
WO/2023/111253A1 |
The method to produce modified mesenchymal cells, in particular for the treatment of renal fibrosis, comprises modifying the cells with a viral vector, in such a way that the modified cells code for a protein which is Decorin; the mesenc...
|
|
WO/2023/111990A1 |
The present invention provides, in part, compounds and methods for treating diseases mediated by PHD1 activity (e.g., ischemia reperfusion injury (including but not limited to stroke, myocardial infarction, and acute kidney injury) infla...
|
|
WO/2023/111907A1 |
The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosur...
|
|
WO/2023/113356A1 |
The present invention relates to a pharmaceutical composition for preventing or treating vascular calcification, containing, as an active ingredient, a Cornus controversa Hemsl. extract, wherein the Cornus controversa Hemsl. extract inhi...
|
|
WO/2023/109471A1 |
Provided are a compound as represented in general formula (I), and a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate or a pharmaceutically acceptable salt or a precursor drug thereof, and a preparatio...
|
|
WO/2023/113114A1 |
The present invention relates to: a novel quinazoline-based compound for activating BKCa channels; and a use thereof for preventing or treating an overactive bladder. The compound of the present invention can effectively activate BKCa ch...
|
|
WO/2023/106256A1 |
As a modified adeno-associated virus (AAV) vector having excellent infection directionality to epithelial cells typified by inner ear epithelial cells, provided is a modified AAV vector in which some amino acid residues in the capsid seq...
|
|
WO/2023/102022A1 |
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula (I), tautomers thereof, deuterated derivatives of those compounds or tautomers, and phar...
|
|
WO/2023/100061A1 |
The present invention refers to compounds of Formula (I) as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders for the treatment of e.g. diabetes, kidney diseases, NASH and heart failure. Preferred compounds ...
|
|
WO/2023/099902A1 |
An ion channel modulator for use in the treatment of cancer and/or metastasis is provided. The ion channel modulator is capable of facilitating ion flow through sodium leak channel (NALCN). A pharmaceutical composition comprising an ion ...
|
|
WO/2023/097980A1 |
Use of a cationic polymer in the preparation of a drug for preventing or treating diseases caused by a toxin produced by intestinal microorganisms or diseases caused by a novel coronavirus infection. The chronic inflammations and various...
|
|
WO/2023/101981A1 |
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
|
|
WO/2023/100380A1 |
[Problem] In the present invention, the action of DHMBA on metastatic human prostate cancer cells (PC-3 and DU-145) is examined. As a result, it is confirmed that DHMBA inhibits the growth of prostate cancer cells and enhances the death ...
|
|
WO/2023/100764A1 |
The composition of the present invention contains, as active ingredients, the following ingredients (1) to (4). Ingredient (1): at least one crude drug selected from the group consisting of honey-fried licorice, licorice, Dioscorea jap...
|
|
WO/2023/095024A1 |
The present invention relates to the use of nexrutine or its compositions in the preventive or curative treatment of stage I prostate cancer in a specific subset of patients.
|
|
WO/2023/096326A1 |
The present invention relates to a composition comprising LGK974 for preventing or treating inflammatory renal disease, and a treatment method. LGK974 reduces, in the kidney, inflammatory cytokines or chemokines such as TNF-α, IFN-γ, I...
|
|
WO/2023/094904A1 |
The present invention describes a composition, comprising propolis and quercetin, for the treatment of genitourinary disorders, in particular of those having an inflammatory nature, and associated symptoms.
|
|
WO/2023/095802A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2023/093845A1 |
A chimeric compound for targeted degradation of androgen receptor protein, a preparation method therefor, and a medical use thereof. Specifically, the present invention relates to a spiro compound represented by general formula (I), a pr...
|
|
WO/2023/091807A1 |
Methods of detecting the presence of one copy or 2 copies of a minor allele of one or more single nucleotide polymorphisms selected from the group consisting of SNP A3_117040611, SNP A3_117041908 and SNP A3_117081913 are disclosed. Metho...
|
|
WO/2023/088272A1 |
Provided are an underglycosylated kallikrein I (KLK1) subjected to no glycosylation or only a small amount of glycosylation at an NFS sequence, and a polyethylene glycol modifier thereof and the pharmaceutical use thereof. Compared with ...
|
|
WO/2023/089338A1 |
The present invention provides a clostridial neurotoxin for use in a method of suppressing visceral pain in a patient. The method comprises: (a) identifying an organ in the patient that is causing said visceral pain; (b) mapping said org...
|
|
WO/2023/090411A1 |
Provided is a pharmaceutical composition for treating and/or preventing at least one among heart disease, heart disease complications, skeletal muscle disease, and skeletal muscle disease conditions, the pharmaceutical composition having...
|
|
WO/2023/090542A1 |
The present invention relates to a composition for preventing or treating benign prostatic hyperplasia, the composition containing, as an active ingredient, an extract of the fruit of Vaccinium bracteatum thunb. The composition inhibits ...
|
|
WO/2023/088427A1 |
An siRNA targeting angiotensinogen (AGT) and a pharmaceutical use of the siRNA. Specifically, the present invention relates to the siRNA targeting an AGT gene, an siRNA conjugate or a dsRNA, a composition, and a pharmaceutical use of the...
|
|
WO/2023/089612A1 |
The invention generally concerns peripherally restricted CB1 antagonists for treatment of LUTS.
|
|
WO/2023/083195A1 |
Provided in the present invention are the preparation for a chimeric antigen receptor immune cell constructed on the basis of a growth arrest-specific protein 6 and the use of the chimeric antigen receptor immune cell. Specifically, prov...
|
|
WO/2023/085397A1 |
Provided is a detection method for Hunner-type interstitial cystitis diagnosis markers, the detection method detecting, from the urine of a subject, the presence amount of at least one microorganism selected from the group consisting of ...
|
|
WO/2023/085396A1 |
The present invention relates to providing a pharmaceutical composition that is useful for treating Alport syndrome. The present invention provides a pharmaceutical composition that is useful for treating Alport syndrome and contains a c...
|
|
WO/2023/084198A1 |
The present disclosure relates to a method of treating or preventing a disease in an individual, the method comprising reducing pyroptosis by administering to the individual a composition comprising an agent whose administration reduces ...
|
|
WO/2023/086465A1 |
The present disclosure provides LNPs comprising payload molecules, e.g., mRNA therapeutics, for the treatment of diseases or disorders, which would benefit from delivery of payload molecules to airway cells.
|
|
WO/2023/085402A1 |
Provided is a novel peptide molecule having an inhibitory activity on the formation of leukocyte extracellular traps. In the description, a peptide molecule having a structure containing an amino acid sequence represented by formula (1) ...
|
|
WO/2023/085415A1 |
Provided is a compound represented by formula (1), or a pharmaceutically acceptable salt thereof. [In the formula, R1 denotes a hydrogen atom, an alkyl group, an alkoxy group or an alkoxyalkyl group, each R2 moiety independently denotes ...
|
|
WO/2023/086003A1 |
The present invention provides IdeS polypeptide for use in a method of treating or pre- venting a disease mediated by pathogenic polymeric IgA complexes, wherein said dis- ease or disorder is progressive IgA nephropathy (IgAN) or recurre...
|
|
WO/2023/085420A1 |
The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction...
|
